The Assurex Health Scientific Advisory Board guides continuing innovation of GeneSight® technology.
Brian D. Athey, Ph.D.
Brian D. Athey is the Michael A. Savageau Collegiate Professor, Chair of the Department of Computational Medicine and Bioinformatics, and Professor of Psychiatry and Internal Medicine at the University of Michigan. Dr. Athey is the founding principal investigator at the NIH National Center for Integrative Biomedical Informatics (NCIBI), one of eight NIH National Biomedical Computing Centers, funded by the National Institute on Drug Abuse (NIDA) and the NIH Common Fund. Dr. Athey also serves as the Co-CEO of the tranSMART Foundation, a non-profit company founded to coordinate the continued development of the open source tranSMART code base which supports an integrated open data sharing and analytics platform used world-wide to accelerate clinical and translational research. He has over 100 peer-reviewed scientific publications and proceedings focusing on bioinformatics, metabolomics, chromatin structure, computational biology, optical imaging, and grid computing. Dr. Athey received his B.S. from St. John’s College in Annapolis, Maryland and his Ph.D. in Cellular and Molecular Biology (Biophysics concentration) from the University of Michigan in Ann Arbor, Michigan.
To learn more about Dr. Athey, please visit University of Michigan’s website.
Learn more about Dr. Athey’s research at PubMed.
Mark S. Boguski, M.D., Ph.D., FCAP
Mark S. Boguski is on the faculty of Harvard Medical School and Beth Israel Deaconess Medical Center in Boston where he founded the Genomic Medicine Initiative in 2009. Dr. Boguski is a pioneer in the fields of bioinformatics and genomics and has previously held faculty positions at the Johns Hopkins University School of Medicine, the U.S. National Institutes of Health, the U.S. National Library of Medicine and as an executive in the biotechnology and pharmaceutical industries. He is a former vice president of Novartis and a Visionary and Influencer according to the Personalized Medicine Coalition. Dr. Boguski is a member of the Institute of Medicine of the U.S. National Academies, the American College of Medical Informatics, the Society for Participatory Medicine and is also a Fellow of the College of American Pathologists. He is a graduate of the Medical Scientist Training Program at Washington University in St. Louis.
To learn more about Dr. Boguski, please visit Precision Medicine Network’s website.
Learn more about Dr. Boguski’s research at PubMed
Tracy A. Glauser, M.D.
Tracy A. Glauser is Associate Director, Cincinnati Children’s Research Foundation and Professor of Pediatrics, Director of the Comprehensive Epilepsy Center, and Co-Director of the Genetic Pharmacology Service at Cincinnati Children’s Hospital Medical Center. Dr. Glauser currently directs the NIH funded Childhood Absence Epilepsy clinical trial involving 29 pediatric centers around the United States and has been the principal investigator on multiple NIH grants. Dr. Glauser’s fields of expertise are pediatric neurology, pediatric epilepsy, clinical pharmacology, and pharmacogenomics, and he has published more than 175 articles and book chapters, and is a co-inventor of Assurex technology. Dr. Glauser received his M.D. from Jefferson Medical College in Philadelphia, Pennsylvania and he completed his residency in pediatrics at the John Hopkins Hospital in Baltimore, Maryland. Dr. Glauser also completed a fellowship in child neurology at The Children’s Hospital of Philadelphia, University of Pennsylvania in Philadelphia, Pennsylvania, and a fellowship in epilepsy and electroencephalography at St. Louis Children’s Hospital in St. Louis, Missouri.
To learn more about Dr. Glauser, please visit Cincinnati Children’s Hospital Medical Center website.
Learn more about Dr. Glauser’s research at PubMed.
James L. Kennedy, M.D., FRCP(C), FRSC
James L. Kennedy is Director of Neuroscience Research at the Tannenbaum Centre for Pharmacogenetics, and Professor in the Department of Psychiatry at the University of Toronto. Dr. Kennedy has training in three major areas: neuroscience, clinical psychiatry, and molecular genetics, with his main research focus over the past 20 years in the identification of susceptibility genes for psychiatric disorders. Dr. Kennedy has published more than 440 scientific articles with over 20,000 citations, and he is an active lecturer at numerous international conferences. A major current project led by Dr. Kennedy is examining a large sample of 20,000 patients to determine the usefulness and cost-benefit of pharmacogenomic testing applied to the clinical choice and dosage of psychiatric medications. Dr. Kennedy received his B.Sc. and M.Sc. from York University in Toronto, Canada and his M.D. from the University of Calgary in Alberta, Canada.
To learn more about Dr. Kennedy, please visit the CAMH website.
Learn more about Dr. Kennedy’s research at PubMed.
Lawrence J. Lesko, Ph.D., FCP
Lawrence J. Lesko is Clinical Professor and Director of the Center for Pharmacometrics and Systems Pharmacology at the University of Florida’s Research and Academic Center in Orlando. Dr. Lesko served as Director of the Office of Clinical Pharmacology in the Food and Drug Administration’s Center for Drug Evaluation and Research from 1995-2011. He was also Chair of the Clinical Pharmacology Coordinating Subcommittee of the FDA’s Medical Policy Coordinating Committee and started the FDA’s Voluntary Genomics Data Submission Program and Mechanistic Drug Safety Programs. Dr. Lesko has published more than 200 peer-reviewed manuscripts, and is frequently an invited speaker in clinical pharmacology, personalized medicine, pharmacometrics, and systems pharmacology. His research includes drug development and regulatory science, quantitative clinical pharmacology, and pharmacogenomics. Dr. Lesko received his B.S. and Ph.D. degrees from Temple University in Philadelphia, Pennsylvania and Advanced Executive Training at the Federal Executive Institute in Charlottesville, Virginia.
To learn more about Dr. Lesko, please visit University of Florida, College of Pharmacy’s website.
Learn more about Dr. Lesko’s research at PubMed.
John P. Pestian, Ph.D., M.B.A.
John P. Pestian is Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center and a Professor of Computer Science at the University of Cincinnati. He is the founding Director of the Division of Biomedical Informatics and the Director of the Computational Medicine Center. Dr. Pestian’s research at Cincinnati Children’s Hospital focuses on developing novel ways to apply advanced technology in the treatment of neuropsychiatric diseases, including epilepsy, and in suicide prediction. He has published multiple research articles and patents and is a co-inventor of Assurex Health technology. Dr. Pestian received his B.S. from St. Francis College in Loreto, Pennsylvania and his M.B.A. from the University of Steubenville in Steubenville, Ohio. He received his Ph.D. from Virginia Commonwealth University in Richmond, Virginia.
To learn more about Dr. Pestian, please visit Cincinnati Children’s Hospital Medical Center website.
Learn more about Dr. Pestian’s research at PubMed.
Sheldon H. Preskorn, M.D.
Sheldon H. Preskorn is Professor in the Department of Psychiatry at the University of Kansas School of Medicine-Wichita (KUSM-W) and Chief Science Officer for the KUSM-W Clinical Trials Unit. A fellow of the American Psychiatric Association and the American Psychopathological Association, Dr. Preskorn has served on advisory committees of the FDA, VA, NIH, and National Science Foundation. Dr. Preskorn has published over 500 scientific, professional articles and books. His clinical research has included pharmacokinetics, drug-drug interactions, and drug development through all clinical phases, from “first time in man” studies through phase III trials. Dr. Preskorn received his M.D. at the University of Kansas. He completed his residency in anatomical pathology and one-year rotating internship in internal medicine and psychiatry at the University of Kansas Medical Center and his residency in psychiatry at Washington University School of Medicine, St. Louis, Missouri.
To learn more about Dr. Preskorn, please visit Preskorn.com.
Learn more about Dr. Preskorn’s research at PubMed.
Wolfgang Sadee, Dr.rer.nat
Wolfgang Sadee is the Felts Mercer Professor of Medicine and Pharmacology, Chair, Department of Pharmacology, Director of the Center for Pharmacogenomics, and Professor of Psychiatry, Pharmacy, and Medical Genetics at The Ohio State University. He is also a DHLRI investigator at the Davis Heart & Lung Research Institute and a member at the OSU Comprehensive Cancer Center. As a member of the NIGMS Pharmacogenomics Research Network III, Dr. Sadee is leading the project “Expression Genetics in Drug Therapy”. Dr. Sadee’s research focuses on pharmacogenomics, employing genomics technologies to discover regulatory variants affecting disease risk and drug response, and developing biomarker tests for optimizing individualized therapies. He has published over 350 research papers, chapters, and monographs, and served as founding editor of Pharmaceutical Research and The AAPS Journal. Dr. Sadee received his Ph.D. in Pharmaceutical Chemistry at the Free University of Berlin in Berlin, Germany.
To learn more about Dr. Sadee, please visit The Ohio State University, College of Medicine’s website.
Learn more about Dr. Sadee’s research at PubMed.
Nicholas J. Schork, Ph.D.
Nicholas J. Schork is a Professor and Director of Human Biology at the J. Craig Venter Institute (JCVI) and an adjunct Professor of Psychiatry and Family and Preventive Medicine (Division of Biostatistics) at the University of California, San Diego (UCSD). A member of several scientific journal editorial boards, Dr. Schork is a frequent participant in U.S. National Institutes of Health-related steering committees and review boards, and has founded or served on the advisory boards of ten companies. In addition, he is currently director of the quantitative components of a number of national research consortia, including the NIA-sponsored Longevity Consortium and the NIMH-sponsored Bipolar Consortium. Dr. Schork’s interests and expertise are in quantitative human genetics and integrated approaches to complex biological and medical problems, especially the design and implementation of methodologies to dissect the determinants of complex traits and diseases. He has published over 450 scientific articles and book chapters on the analysis of complex, multifactorial traits and diseases. Dr. Schork earned the B.A. in Philosophy, M.A. in Philosophy, M.A. in Statistics, and Ph.D. in Epidemiology, all from the University of Michigan in Ann Arbor.
To learn more about Dr. Schork, please visit the JVCI website.
Learn more about Dr. Schork’s research at PubMed.